The PharmaTimes Marketer of the Year Awards will return to London in November, alongside Communications Team of the Year and the all-new Sales Awards. Get involved with the 25th anniversary celebrations as this unique competition continues to raise standards, drive innovation and put patient outcomes at the centre of healthcare marketing.
If not, you should. Now!Dr Jim Golby PhD FCIPD, co-chair of the competition’s executive steering group (ESG) says: "I strongly believe that the newly imagined 2018 Pharma Sales Awards will provide a superb methodology for identifying and recognising the very best sales professionals in our Industry today.”
A combination of AbbVie/Johnson & Johnson’s Imbruvica and Roche’s Gazyva has taken a step closer to becoming first chemotherapy-free CD20 combination for first-line treatment of chronic lymphocytic leukaemia (CLL), after showing promise in a late-stage clinical trial.
The National Institute for Health and Care Excellence has issued draft guidelines backing restricted use of Pfizer’s Mylotarg for newly diagnosed acute myeloid leukaemia (AML), but has asked for more information on the firm’s Besponsa for a type of acute lymphoblastic leukaemia (ALL).
It is currently looking unlikely that Chiesi’s Lamzede will become routinely available on the NHS for patients with alpha-mannosidosis, after cost-regulators issued a preliminary rejection of the drug.
Tax rises will likely be needed to keep the quality of health and social care as it is now while the system contends with the growing demands of an ageing demographic, concludes a report by The Institute for Fiscal Studies and the Health Foundation.
The European Commission has expanded the scope of Amgen’s PCSK9 inhibitor Repatha to include the reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease (CVD).